Research programme: cancer therapeutics - Cyteir Therapeutics

Drug Profile

Research programme: cancer therapeutics - Cyteir Therapeutics

Alternative Names: RAD51-AID

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Cyteir Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Rad51 recombinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma; Leukaemia; Type 1 diabetes mellitus

Most Recent Events

  • 01 Jun 2017 Preclinical trials in Type-1 diabetes mellitus in USA before June 2017 (Parenteral)
  • 01 Jun 2017 Pharmacodynamics data from a preclinical study in Type-1 diabetes mellitus released by Cyteir Therapeutics
  • 28 Mar 2017 Preclinical trials in Leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top